A piece in the puzzle: An ion channel candidate gene for schizophrenia

Molecular Medicine Today

Volumn 4, Issue 12, 1998, Pages 518-524

  Gargus, J Jay ^a   Fantino, Emmanuelle ^a   Gutman, George A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; POTASSIUM CHANNEL;

GENE EXPRESSION; HUMAN; ION TRANSPORT; REVIEW; SCHIZOPHRENIA;

EID: 0031742638     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01358-6     Document Type: Article

References (49)

1. Karayiorgou M., Gogos J.A. A turning point in schizophrenia genetics. Neuron. 19:1997;967-979.
2. O'Donovan M.C., Owen M.J. The molecular genetics of schizophrenia. Ann. Med. 28:1996;541-546.
3. Cloninger, C.R. (1994) Tests of alternative models of the relationship of schizophrenic and affective psychoses, in Genetic Approaches to Mental Disorders (Gershon, E.S. and Cloninger, C.R., eds), pp. 149-162, American Psychiatric Press.
4. Ashley C.T. Jr., Warren S.T. Trinucleotide repeat expansion and human disease. Annu. Rev. Genet. 29:1995;703-728.
5. O'Donovan M.C.et al. Expanded CAG repeats in schizophrenia and bipolar disorder. Nat. Genet. 10:1995;380-381.
6. O'Donovan M.C.et al. Confirmation of association between expanded CAG/CTG repeats and both schizophrenia and bipolar disorder. Psychol. Med. 26:1996;1145-1153.
7. Morris A.G.et al. CAG repeat expansions and schizophrenia: association with disease in females and with early age-at-onset. Hum. Mol. Genet. 4:1995;1957-1961.
8. Johnson J.E.et al. Anticipation in schizophrenia: biology or bias? Am. J. Med. Genet. 74:1997;275-280.
9. Guy C.et al. Exclusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder. Am. J. Psychiatry. 154:1997;1146-1147.
10. Bowen T.et al. Expansion of 50 CAG/CTG repeats excluded in schizophrenia by application of a highly efficient approach using repeat expansion detection and a PCR screening set. Am. J. Hum. Genet. 59:1996;912-917.
11. Rubinsztein D.C.et al. Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. Am. J. Med. Genet. 67:1996;495-498.
12. Speight G.et al. Exclusion of CAG/CTG trinucleotide repeat loci which map to human chromosome 4 in bipolar disorder and schizophrenia. Am. J. Med. Genet. 74:1997;204-206.
13. Margolis R.L.et al. cDNAs with long CAG trinucleotide repeats from human brain. Hum. Genet. 100:1997;114-122.
14. Kaku D.A., Giffard R.G., Choi D.W. Neuroprotective effects of glutamate antagonists and extracellular acidity. Science. 260:1993;1516-1518.
15. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
16. Moghaddam B.et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
17. Hirsch S.R.et al. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol. Biochem. Behav. 56:1997;797-802.
18. Yamamoto J. Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine. Psychopharmacology. 131:1997;379-387.
19. Banerjee S.P.et al. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. NeuroReport. 6:1995;2500-2504.
20. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4757-4760.
21. Ishimaru M., Kurumaji A., Toru M. Glutamate receptors and schizophrenia. Trends Neurosci. 19:1996;416-417.
22. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
23. Sucher N.J.et al. NMDA receptors: from genes to channels. Trends Pharmacol. Sci. 17:1996;348-355.
24. Nicoll R.A. The coupling of neurotransmitter receptors to ion channels in the brain. Science. 241:1988;545-551.
25. + currents. Neurosci. Lett. 231:1997;13-16.
26. Schafer A.J., Hawkins J.R. DNA variation and the future of human genetics. Nat. Biotechnol. 16:1998;33-39.
27. Kohler M.et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 273:1996;1709-1714.
28. Ishii T.M.et al. A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11651-11656.
29. Joiner W.J.et al. hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11013-11018.
30. Chandy K.G.et al. Isolation of a potassium channel gene, hSKCa3, containing polymorphic CAG repeat: A candidate gene for schizophrenia and bipolar disorder? Mol. Psychiatry. 3:1998;32-37.
31. + channel gene hKCa3: a candidate gene for schizophrenia and bipolar disorder? Biophys. J. 74:1998;A26.
32. Zhuchenko O.O.et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15:1997;62-69.
33. Ishikawa K.et al. Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. Am. J. Hum. Genet. 61:1997;336-346.
34. Reiss O.et al. SCA6 is caused by moderate CAG expansion in the alpha-1A-voltage-dependent calcium channel gene. Hum. Mol. Genet. 6:1997;1289-1293.
35. Matsuyama Z.et al. Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6). Hum. Mol. Genet. 6:1997;1283-1287.
36. Jodice C.et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum. Mol. Genet. 6:1997;1973-1978.
37. 2+ channel gene CACNL1A4. Cell. 87:1996;543-552.
38. Bates G.P., Davies S.W. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. Mol. Med. Today. 3:1997;508-515.
39. Perutz M.F. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6:1996;848-858.
40. Bowen T.et al. Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Mol. Psychiatry. 3:1998;266-269.
41. Navon R.et al. Strong association between schizophrenia and long CAG repeats in hKCa3/KCNN3 gene, mapped to 1Q21, among Israeli jews. Am. J. Hum. Genet. 63:1998;A337.
42. McKusick V.A. Genomics: structural and functional studies of genomes. Genomics. 45:1997;244-249.
43. Davies K. Up the function. Nat. Genet. 16:1997;111-112.
44. Robertson D.W., Steinberg M.I. Potassium channel modulators: scientific applications and therapeutic promise. J. Med. Chem. 33:1990;1529-1541.
45. Lehmann-Horn F., Rüdel R. Molecular pathophysiology of voltage-gated ion channels. Rev. Physiol. Biochem. Pharmacol. 128:1996;195-268.
46. Ackerman M.J., Clapham D.E. Ion channels-basic science and clinical disease. New Engl. J. Med. 336:1997;1575-1586.
47. + channel genes, in CRC Handbook, pp. 1-76.
48. Wei A., Jegla T., Salkoff L. Eight potassium channel families revealed by the C. elegans genome project. Neuropharmacology. 35:1996;805-829.
49. Jan L.Y., Jan Y.N. Cloned potassium channels from eukaryotes and prokaryotes. Annu. Rev. Neurosci. 20:1997;91-123.